Volume : 09, Issue : 12, December – 2022
Title:
30.FORMULATION OF DELAYED RELEASE OMEPRAZOLE FOR THE TREATMENT OF ACTIVE DUODENUM ULCER
Authors :
Ms. Jaya Pandey*, Mrs. Jyoti Thakur
Abstract :
Duodenal ulcers are part of a broader disease state categorized as peptic ulcer diseaseWhile most duodenal ulcers present with dyspepsia as the primary associated symptom, the presentation can range in severity levels, including gastrointestinal bleeding, gastric outlet obstruction, perforation, or fistula development. Proton-pump inhibitors (PPIs) have been very efficacious for the management of ulcer. Omeprazole degrades very rapidly in aqueous solutions at low pH values. Omeprazole degradation is acid-catalysed; with an increase in the pH values, the rate of degradation decreases. So, delivery of therapeutic agent into the intestinal region could be accomplished by the application of an enteric coating on a solid dosage form. So, the aim of this study is formulation of delayed release Omeprazole for treatment of Duodenal ulcers. The formulation & evaluation of formulated drug was done according to standard procedures. Particle size analysis result shows that 90 % of particles were in range of 36.031 to 37.592 µm. which showed uniformity of particle size. Moisture content was found to be 0.3%.Weight variation data of core tablets formulated using both direct compression and wet granulation indicated that they were in range of official standards and no significant difference between individual weights of tablets from the average value. Formulation F008 formulated by 4mg of PVP K 30 per tablet along with IPA shows highest drug release among other batches core tablet by wet granulation method. Thus Formulation F008 posses delayed release property so can be used to cure duodenal ulcers.
Keywords: Duodenal ulcers, Omeprazole, Delayed release, Tablet
Cite This Article:
Please cite this article in press Jaya Pandey et al, Formulation Of Delayed Release Omeprazole For The Treatment Of Active Duodenum Ulcer.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311-5.
3. Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med. 1996 May 20;100(5A):12S-17S; discussion 17S-18S.
4. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995;9 Suppl 2:33-9.
5. Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Medical Clinics. 2002 Nov 1;86(6):1447-66.
6. Horn JR, Howden CW. Similarities and differences among delayed‐release proton‐pump inhibitor formulations. Alimentary pharmacology & therapeutics. 2005 Dec;22:20-4.
7. Corsonello A, Lattanzio F, Bustacchini S, Garasto S, Cozza A, Schepisi R, Lenci F, Luciani F, Maggio MG, Ticinesi A, Butto V. Adverse events of proton pump inhibitors: potential mechanisms. Current drug metabolism. 2018 Feb 1;19(2):142-54.
8. Clissold SP, Campoli-Richards DM. Omeprazole. Drugs. 1986 Jul;32(1):15-47.
9. Wilde MI, McTavish D. Omeprazole. Drugs. 1994 Jul;48(1):91-132.
10. Splendor D, Gonçalves IM, Costa P, Sousa Lobo JM. Note on the measurement of bulk density and tapped density of powders according to the European Pharmacopeia. AAPS PharmSciTech. 2013 Sep;14(3):1098-100.
11. Grey RO, Beddow JK. On the Hausner ratio and its relationship to some properties of metal powders. Powder Technology. 1969 Sep 1;2(6):323-6.
12. Al-Hashemi HM, Al-Amoudi OS. A review on the angle of repose of granular materials. Powder technology. 2018 May 1;330:397-417.
13. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. International Journal of Pharmaceutics. 1989 Apr 1;51(1):9-17.
14. Bravo-Osuna I, Ferrero C, Jiménez-Castellanos MR. Drug release behaviour from methyl methacrylate-starch matrix tablets: effect of polymer moisture content. European journal of pharmaceutics and biopharmaceutics. 2008 May 1;69(1):285-93.
15. Freire E. Differential scanning calorimetry. Protein stability and folding. 1995:191-218.
16. Schlich M, Lai F, Maria Fadda A, Sinico C, Pini E. Drug-Excipients Compatibility Studies in Proniosomal Formulation: A Case Study with Resveratrol. Journal of Nanoscience and Nanotechnology. 2021 May 1;21(5):2917-21.
17. Agyilirah GA, Green M, Banker GS. Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a non-disintegrating tablet. International journal of pharmaceutics. 1991 Sep 20;75(2-3):241-7.
18. Vitz J, Erdmenger T, Haensch C, Schubert US. Extended dissolution studies of cellulose in imidazolium based ionic liquids. Green chemistry. 2009;11(3):417-24.